The global Liquid Biopsy Market size is expected to reach USD 19.35 billion by 2028, registering a CAGR of 13.5% during the forecast period, according to a new report by Grand View Research, Inc. It is a revolutionary technique that has created various opportunities that were previously unexplored.
It aids in the detection and isolation of circulating
tumor DNA, exosomes, and circulating tumor cells and is a source of proteomics
and genomics information in cancer patients. Rapid development in
digital Polymerase Chain Reaction (PCR) and NGS-based technology has
improved the accuracy of liquid biopsy. It can be performed repeatedly for
disease monitoring and is anticipated to help overcome the limitations of
tissue biopsies.
As liquid biopsies are the most promising novel
techniques for cancer care, established as well as emerging companies have
increased their R&D to develop novel liquid biopsy solutions. For instance,
in September 2021, AnchorDx Medical Co., Ltd.; a China-based developer of early
cancer detection and oncology screening solutions developed a diagnostic model
for early breast cancer detection. The model is based on the methylation
patterns of cfDNA.
Related Press Release@ Liquid Biopsy Market Report
Liquid Biopsy Market Report
Highlights
- The Multi-gene Parallel Analysis (NGS) technology segment held the
largest revenue share of the global market in 2020
- This can be attributed to rapid enhancements in NGS technology.
With this technology, liquid biopsies are anticipated to gain considerable
importance in cancer-related studies and research
- On the basis of sample type, blood sample-based tests dominated the
market in 2020
- Blood samples can readily be taken at a more frequent interval,
thus increasing the adoption rate
- Circulating Nucleic Acids are the most commonly used biomarker for
liquid biopsy tests
- The factors, such as the constantly evolving pipeline of
ctDNA-based liquid biopsy tests, an increasing number of commercialized
products, and the potential of ctRNA in determining molecular profile have
contributed to the dominance of this segment
- North America is expected to be the largest revenue-generating
region by 2028 owing to a high incidence of cancer, rapid technological
advancements, and the presence of key players in the region
- Key players are focused on business expansion through product
launches, mergers & acquisitions, agreements, partnerships, and other
growth strategies
- For instance, in June 2021, Biocept, Inc. collaborated with Quest
Diagnostics to provide advanced NGS-based liquid biopsy testing for lung
cancer patients
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment